Longevity Science — 2026-06-05

Top Research Findings

1. Rapamycin Matches Caloric Restriction for Lifespan Extension in New Study

A recent study comparing rapamycin to dietary restriction (DR) found that the immunosuppressant drug extends lifespan comparably to caloric restriction alone, with no significant sex-specific differences in efficacy. The research suggests benefits are similar for both males and females, indicating rapamycin's potential as a non-behavioral longevity intervention.

2. Harvard Publishes Longevity Report for General Public

Harvard released "Pathways to Longevity," a comprehensive report introducing key longevity science concepts to the general public, marking another sign the field is entering mainstream scientific discourse. The report integrates recent scientific advancements with practical advice for healthy aging.

3. Frontiers Reviews Rapamycin's Longevity Potential and Limitations

A comprehensive peer-reviewed analysis in Frontiers in Aging examines rapamycin's dual role in anti-aging research—highlighting both efficacy and safety concerns. The review underscores that while lifespan extension is documented, off-target effects and immunosuppression remain important considerations for therapeutic use.

1 sources

lifespan.io

lifespan.io

Clinical Trials & Intervention Updates

PEARL (Participatory Evaluation of Aging With Rapamycin for Longevity)

The PEARL trial continues enrolling healthy adults to assess rapamycin's effects on aging phenotypes in humans. Early data suggests the drug influences muscle and bone aging markers, though participants reported more frequent chronic condition flare-ups alongside reduced symptom severity compared to placebo. This trade-off between efficacy and tolerability remains a key question for human longevity therapies.

MILES (Metformin in Longevity Study)

The MILES trial, investigating metformin as a potential longevity intervention in non-diabetic populations, continues recruitment. Metformin's role in extending healthspan independent of weight loss remains an active area of clinical evaluation.

Industry & Biotech Watch

NewLimit Raises $435M After Demonstrating Age Reversal in Human Liver Cells

NewLimit announced a landmark $435 million funding round after its epigenetic reprogramming technology reversed aging markers in human liver cells—years ahead of the company's original clinical timeline. The funding will support an imminent first-in-human liver trial, accelerating the path from bench to bedside. This represents one of the largest single raises in the longevity biotech sector and signals investor confidence in partial cellular reprogramming approaches.

Retro Biosciences Valued at $1.8 Billion in Latest Fundraising

The OpenAI CEO Sam Altman-backed longevity startup Retro Biosciences achieved a $1.8 billion valuation in a recent funding round, cementing institutional investor appetite for cellular rejuvenation platforms. The company continues development of its cellular reprogramming approach targeting age-related disease.

Deep Dive: Intervention Evidence Check — Rapamycin for Longevity

The Current State of Evidence

Rapamycin (sirolimus), originally developed as an immunosuppressant and anti-cancer agent, has become one of the most discussed compounds in longevity science. Here's what the evidence actually shows:

Human Data (Limited but Growing):

• The PEARL trial is the first long-term human evaluation, with preliminary results suggesting effects on muscle and bone aging markers
• No completed human lifespan extension trials in healthy people yet
• Early data shows more frequent flare-ups of chronic conditions but also reduced symptom severity—a net effect still unclear

Animal Data (Extensive):

• Robust lifespan extension documented in mice, rats, and other models
• Effects comparable to caloric restriction in some studies
• Benefits appear independent of sex

What Remains Speculative:

• Whether rapamycin will extend human lifespan meaningfully
• Optimal dosing and dosing schedules for longevity (vs. immunosuppression)
• Long-term safety profile in healthy, non-transplant populations
• Whether off-target immunosuppressive effects offset longevity gains

Bottom Line for Readers: Rapamycin shows genuine promise in animals and early human studies, but human longevity data remains preliminary. Anyone considering rapamycin off-label should discuss risks (infection, metabolic changes, potential cancer interactions) with a physician experienced in longevity medicine. It is not yet an evidence-backed consumer supplement and remains a prescription drug.

What to Watch Next

• NewLimit's human liver trial initiation (expected within months): First clinical proof-of-concept for epigenetic reprogramming in aging
• Harvard's longevity report uptake: Tracking whether mainstream media and public health messaging incorporate the field's emerging consensus
• PEARL trial interim readouts: Expected mid-to-late 2026 on muscle, bone, and metabolic outcomes with rapamycin
• InsideTracker's AI platform pivot: The company's shift from consumer biomarker testing to enterprise AI-driven health intelligence may signal broader industry consolidation around predictive aging metrics

Reader Action Items

1. Discuss rapamycin with your longevity-informed physician if you're interested, but understand human evidence remains preliminary. Caloric restriction and exercise have longer human safety records and proven benefits.

2. Read Harvard's "Pathways to Longevity" report (free, public-facing): It provides a credible, scientist-vetted overview of major longevity research areas—useful for separating hype from science.

3. Monitor NewLimit's trial results carefully: If epigenetic reprogramming works in humans, it could shift how we think about reversing aging rather than just slowing it. This is an important inflection point to watch.